2-乙基-5-溴噻唑 | 1086382-44-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-乙基-5-溴噻唑
• 英文名称: ethyl-5-bromothiazole
• 英文别名: 5-Bromo-2-ethylthiazole；5-bromo-2-ethyl-1,3-thiazole
• CAS: 1086382-44-6
• 化学式: C₅H₆BrNS
• mdl: MFCD11223412
• 分子量: 192.079
• InChiKey: PMLOCJDQVWVTPZ-UHFFFAOYSA-N

物化性质

• 沸点：
  214.7±13.0 °C(Predicted)
• 密度：
  1.585±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-乙基-5-溴噻唑 在 盐酸 、 正丁基锂 作用下， 以 正己烷 、 丙酮 为溶剂， 反应 6.5h， 生成 4-(2-ethyl-thiazol-5-yl)-4-hydroxy-cyclohexanone
  参考文献：
  名称：

  Discovery of a 4-Azetidinyl-1-thiazoyl-cyclohexane CCR2 Antagonist as a Development Candidate

  摘要：

  We have discovered a novel series of 4-azetidiny1-1-aryl-cyclohexanes as CCR2 antagonists. Divergent SAR studies on hCCR2 and hERG activities led to the discovery of compound 8d, which displayed good hCCR2 binding affinity (IC50, 37 nM) and potent functional antagonism (chemotaxis IC50, 30 nM). It presented an IC50 of >50 mu M in inhibition of the hERG channel and had no effect on the QTc interval up to 10 mg/kg (i.v.) in anesthetized guinea pig and dog CV studies. It also displayed high selectivity over other chemokine receptors and GPCRs, and amendable oral bioavailability in dogs and primates. In a thioglycollate-induced inflammation model in hCCR2KI mice, it had ED50 of 3 mg/kg on inhibition of the influx of leukocytes, monocytes/macrophages, and T-lymphocytes.

  DOI：

  10.1021/ml300260s

文献信息

• Discovery of a 4-Azetidinyl-1-thiazoyl-cyclohexane CCR2 Antagonist as a Development Candidate
  作者：Xuqing Zhang、Cuifen Hou、Heather Hufnagel、Monica Singer、Evan Opas、Sandra McKenney、Dana Johnson、Zhihua Sui

  DOI：10.1021/ml300260s

  日期：2012.12.13

  We have discovered a novel series of 4-azetidiny1-1-aryl-cyclohexanes as CCR2 antagonists. Divergent SAR studies on hCCR2 and hERG activities led to the discovery of compound 8d, which displayed good hCCR2 binding affinity (IC50, 37 nM) and potent functional antagonism (chemotaxis IC50, 30 nM). It presented an IC50 of >50 mu M in inhibition of the hERG channel and had no effect on the QTc interval up to 10 mg/kg (i.v.) in anesthetized guinea pig and dog CV studies. It also displayed high selectivity over other chemokine receptors and GPCRs, and amendable oral bioavailability in dogs and primates. In a thioglycollate-induced inflammation model in hCCR2KI mice, it had ED50 of 3 mg/kg on inhibition of the influx of leukocytes, monocytes/macrophages, and T-lymphocytes.